DPV 001

Drug Profile

DPV 001

Alternative Names: Autophagosome vaccine - UbiVac; Cancer vaccine DRibble; DPV-001 DRibble Vaccine; DPV001; DRibble Vaccine; DRibbles

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator UbiVac
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Prostate cancer

Most Recent Events

  • 12 Sep 2016 UbiVac plans a phase I/II trial for Non-small cell lung cancer(Combination therapy) in USA (UbiVac pipeline, September 2016)
  • 12 Sep 2016 UbiVac plans a phase II trial for Breast cancer (Combination therapy) in USA (UbiVac pipeline, September 2016)
  • 01 Sep 2014 Phase-I clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intralymphatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top